Skip to main content

Table 1 Analysis of PIK3CA mutations per exon and treatment group

From: Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

 

Group A

Group B

Group C

Group D

Overall (pooled groups)

Exon

n (Mut/total)

pCR, n (%)

non-pCR, n (%)

pCR, n (%)

non-pCR, n (%)

pCR, n (%)

non-pCR, n (%)

pCR, n (%)

non-pCR, n (%)

pCR, n (%)

non-pCR, n (%)

Exon 7

n = 2

n = 1

n = 1

n = 0

n = 4

(4/290)

0

2 (100)

0

1 (100)

0

1 (100)

0

0

0

4 (100)

Exon 9

n = 8

n = 5

n = 5

n = 10

n = 28

(28/328)

0

8 (100)

1 (20.0)

4 (80.0)

0

5 (100)

1 (10.0)

9 (90.0)

2 (7.1)

26 (92.9)

Exon 20

n = 20

n = 15

n = 17

n = 14

n = 66

(66/338)

7 (35.0)

13 (65.0)

7 (46.7)

8 (53.3)

2 (11.8)

15 (88.2)

3 (21.4)

11 (78.6)

19 (28.8)

47 (71.2)

  1. Mut mutant, pCR pathologic complete response, PIK3CA gene encoding phosphoinositide 3-kinase, catalytic subunit